
ESCMID AI Course - Day 2: Resistance Prediction Analysis Summary
===============================================================

Dataset: Synthetic Microbiology Data (Cleaned)
Analysis Date: 2025-05-31 22:02
Analysis Type: Antibiotic Resistance & Susceptibility Prediction
Samples: 9635
Clinical Features: 9

Antimicrobial Susceptibility Analysis:

Available Antibiotics Analyzed: 10
Antibiotics with Sufficient Data: 10

Resistance Rates:
- Ampicillin: 66.1%
- Ciprofloxacin: 33.3%
- Levofloxacin: 26.5%
- Gentamicin: 20.3%
- Ceftriaxone: 18.5%
- Meropenem: 9.8%
- Amikacin: 9.2%
- Vancomycin: 1.3%
- Tigecycline: 0.4%
- Linezolid: 0.2%


Single-Drug Resistance Prediction Results:
- Amikacin: Gradient Boosting (AUC = 0.736 ± 0.014)
- Linezolid: SVM (AUC = 0.715 ± 0.235)
- Ceftriaxone: Gradient Boosting (AUC = 0.695 ± 0.024)
- Vancomycin: Gradient Boosting (AUC = 0.692 ± 0.055)
- Meropenem: Gradient Boosting (AUC = 0.674 ± 0.013)
- Ciprofloxacin: Logistic Regression (AUC = 0.671 ± 0.035)
- Gentamicin: Gradient Boosting (AUC = 0.640 ± 0.006)
- Levofloxacin: Gradient Boosting (AUC = 0.598 ± 0.016)
- Tigecycline: SVM (AUC = 0.571 ± 0.067)
- Ampicillin: Gradient Boosting (AUC = 0.570 ± 0.009)


Multi-Drug Resistance (MDR) Prediction Results:
- class_based: Logistic Regression (AUC = 0.692 ± 0.005)
- drug_count: Gradient Boosting (AUC = 0.762 ± 0.016)
- critical_drug: Gradient Boosting (AUC = 0.666 ± 0.024)


Machine Learning Approaches:
1. Single-Drug Prediction: Individual models for each antibiotic
2. Multi-Drug Resistance: Composite resistance definitions
3. Clinical Decision Support: Empirical therapy recommendations

Models Evaluated:
- Logistic Regression
- Random Forest
- Gradient Boosting
- SVM
- Naive Bayes


Feature Engineering:
- Categorical encoding: One-hot encoding for 8 categorical features
- Numerical scaling: StandardScaler for 1 numerical features
- Missing value handling: Imputation with 'Unknown' category

Key Clinical Applications:
1. Empirical Therapy Selection: Predict resistance before culture results
2. Antimicrobial Stewardship: Optimize antibiotic usage patterns
3. Infection Control: Early identification of MDR organisms
4. Quality Assurance: Flag unusual resistance patterns

Performance Insights:
- Species and specimen source are likely key predictors
- Performance varies significantly by antibiotic and prevalence
- Cross-validation provides robust estimates despite class imbalance
- MDR prediction may be more clinically actionable than single drugs

Clinical Considerations:
- High Sensitivity: Critical to avoid missing resistant infections
- Balanced Approach: Consider both effectiveness prediction and stewardship
- Local Validation: Performance may vary by institution and time
- Integration: Must fit into existing laboratory workflows

Next Steps for Clinical Implementation:
1. External Validation: Test on data from different institutions
2. Prospective Studies: Evaluate impact on patient outcomes
3. Regulatory Approval: Meet medical device requirements if applicable
4. Clinical Integration: Develop EMR and laboratory system interfaces
5. Continuous Monitoring: Track performance drift over time
6. Clinician Training: Educate users on appropriate interpretation

Models Saved for Deployment:
- Amikacin: Gradient Boosting (resistance_model_Amikacin.pkl)
- Linezolid: SVM (resistance_model_Linezolid.pkl)
- Ceftriaxone: Gradient Boosting (resistance_model_Ceftriaxone.pkl)
- Vancomycin: Gradient Boosting (resistance_model_Vancomycin.pkl)
- Meropenem: Gradient Boosting (resistance_model_Meropenem.pkl)
- Ciprofloxacin: Logistic Regression (resistance_model_Ciprofloxacin.pkl)
- Gentamicin: Gradient Boosting (resistance_model_Gentamicin.pkl)
- Levofloxacin: Gradient Boosting (resistance_model_Levofloxacin.pkl)
- Tigecycline: SVM (resistance_model_Tigecycline.pkl)
- Ampicillin: Gradient Boosting (resistance_model_Ampicillin.pkl)
- class_based MDR: (mdr_model_class_based.pkl)
- drug_count MDR: (mdr_model_drug_count.pkl)
- critical_drug MDR: (mdr_model_critical_drug.pkl)


Technical Notes:
- All models use balanced class weights to handle imbalanced data
- Stratified cross-validation maintains class distribution across folds
- Performance metrics focus on AUC-ROC for clinical interpretability
- Models include preprocessing pipelines for deployment readiness

Limitations:
- Synthetic data may not reflect real-world complexity
- Limited temporal validation (single time period)
- Missing molecular resistance mechanisms
- Requires validation on external datasets before clinical use

This analysis demonstrates the potential for machine learning to support
clinical decision-making in antimicrobial therapy selection while highlighting
the importance of proper validation and clinical integration considerations.
